Eli Lilly and Company LLY is a key player in the diabetes and obesity drug market, mainly due to the significant popularity ...

Legendary investor Warren Buffett is known for many things, including memorable quotes. Perhaps the most cited is his contrarian philosophy: investors should “be fearful when others are greedy and to ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

This medicine generated $3.6 billion in sales last year. But according to some estimates, the oral GLP-1 market could hit $20 ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Eli Lilly (LLY) is falling today due to reports of progress from competitors. The pharmaceutical producer has struggled recently as its share of the obesity treatment pill market has been threatened.

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), ...

Eli Lilly (LLY) has outperformed the S&P index and its competitors during the past 5 years, LLY has a broad product portfolio, a robust pipeline that is built to power market performance.

Shares of Eli Lilly & Co. LLY shed 1.34% to $715.20 Thursday, on what proved to be an all-around rough trading session for the stock market, with the Dow Jones Industrial Average DJIA remaining ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.